Literature DB >> 25183707

A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy.

Mariana de Carvalho Barbosa1, Alyssa K Kosturakis2, Cathy Eng3, Gwen Wendelschafer-Crabb4, William R Kennedy4, Donald A Simone5, Xin S Wang6, Charles S Cleeland6, Patrick M Dougherty7.   

Abstract

Peripheral neuropathy caused by cytotoxic chemotherapy, especially platins and taxanes, is a widespread problem among cancer survivors that is likely to continue to expand in the future. However, little work to date has focused on understanding this challenge. The goal in this study was to determine the impact of colorectal cancer and cumulative chemotherapeutic dose on sensory function to gain mechanistic insight into the subtypes of primary afferent fibers damaged by chemotherapy. Patients with colorectal cancer underwent quantitative sensory testing before and then prior to each cycle of oxaliplatin. These data were compared with those from 47 age- and sex-matched healthy volunteers. Patients showed significant subclinical deficits in sensory function before any therapy compared with healthy volunteers, and they became more pronounced in patients who received chemotherapy. Sensory modalities that involved large Aβ myelinated fibers and unmyelinated C fibers were most affected by chemotherapy, whereas sensory modalities conveyed by thinly myelinated Aδ fibers were less sensitive to chemotherapy. Patients with baseline sensory deficits went on to develop more symptom complaints during chemotherapy than those who had no baseline deficit. Patients who were tested again 6 to 12 months after chemotherapy presented with the most numbness and pain and also the most pronounced sensory deficits. Our results illuminate a mechanistic connection between the pattern of effects on sensory function and the nerve fiber types that appear to be most vulnerable to chemotherapy-induced toxicity, with implications for how to focus future work to ameloirate risks of peripheral neuropathy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183707      PMCID: PMC4216766          DOI: 10.1158/0008-5472.CAN-14-2060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Neurologic complications of cancer and its treatment.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

Review 2.  Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities.

Authors:  Miroslav-Misha Backonja; David Walk; Robert R Edwards; Nalini Sehgal; Toby Moeller-Bertram; Ajay Wasan; Gordon Irving; Charles Argoff; Mark Wallace
Journal:  Clin J Pain       Date:  2009-09       Impact factor: 3.442

3.  Merkel Cells in Somatosensation.

Authors:  Henry Haeberle; Ellen A Lumpkin
Journal:  Chemosens Percept       Date:  2008-06-01       Impact factor: 1.833

4.  Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Haijun Zhang; Larry C Driver; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  J Pain       Date:  2011-06-24       Impact factor: 5.820

5.  Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.

Authors:  Elisabeth G Vichaya; Xin Shelley Wang; Jessica A Boyette-Davis; Tito R Mendoza; Zijing He; Sheeba K Thomas; Nina Shah; Loretta A Williams; Charles S Cleeland; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-31       Impact factor: 3.333

6.  Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus.

Authors:  Miroslav Misha Backonja; Nadine Attal; Ralf Baron; Didier Bouhassira; Mark Drangholt; Peter J Dyck; Robert R Edwards; Roy Freeman; Richard Gracely; Maija H Haanpaa; Per Hansson; Samar M Hatem; Elena K Krumova; Troels S Jensen; Christoph Maier; Gerard Mick; Andrew S Rice; Roman Rolke; Rolf-Detlef Treede; Jordi Serra; Thomas Toelle; Valeri Tugnoli; David Walk; Mark S Walalce; Mark Ware; David Yarnitsky; Dan Ziegler
Journal:  Pain       Date:  2013-06-03       Impact factor: 6.961

7.  Secondary hyperalgesia persists in capsaicin desensitized skin.

Authors:  P N Fuchs; J N Campbell; R A Meyer
Journal:  Pain       Date:  2000-02       Impact factor: 6.961

8.  Interleukin-1 beta and interferon-gamma induce proliferation and apoptosis in cultured Schwann cells.

Authors:  Giancarlo Conti; Anto De Pol; Elio Scarpini; Fabiana Vaccina; Milena De Riz; PierLuigi Baron; Marco Tiriticco; Guglielmo Scarlato
Journal:  J Neuroimmunol       Date:  2002-03       Impact factor: 3.478

9.  Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline.

Authors:  J Boyette-Davis; P M Dougherty
Journal:  Exp Neurol       Date:  2011-03-05       Impact factor: 5.330

10.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

View more
  25 in total

1.  Comparison between quantitative and subjective assessments of chemotherapy-induced peripheral neuropathy in cancer patients: A prospective cohort study.

Authors:  Takashi Saito; Daisuke Makiura; Junichiro Inoue; Hisayo Doi; Kimikazu Yakushijin; Atsuo Okamura; Hiroshi Matsuoka; Toru Mukohara; Ryuichi Saura; Yoshitada Sakai; Rei Ono
Journal:  Phys Ther Res       Date:  2020-07-22

Review 2.  Update on Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Comana Cioroiu; Louis H Weimer
Journal:  Curr Neurol Neurosci Rep       Date:  2017-06       Impact factor: 5.081

3.  Cold therapy to prevent paclitaxel-induced peripheral neuropathy.

Authors:  Claire Griffiths; Nancy Kwon; Jennifer L Beaumont; Judith A Paice
Journal:  Support Care Cancer       Date:  2018-04-21       Impact factor: 3.603

Review 4.  Can Stopping Nerves, Stop Cancer?

Authors:  Jami L Saloman; Kathryn M Albers; Andrew D Rhim; Brian M Davis
Journal:  Trends Neurosci       Date:  2016-11-08       Impact factor: 13.837

Review 5.  Mechanisms involved in the development of chemotherapy-induced neuropathy.

Authors:  Jessica A Boyette-Davis; Edgar T Walters; Patrick M Dougherty
Journal:  Pain Manag       Date:  2015-06-19

6.  Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study.

Authors:  Susana Pereira; Filipa Fontes; Teresa Sonin; Teresa Dias; Maria Fragoso; José M Castro-Lopes; Nuno Lunet
Journal:  Support Care Cancer       Date:  2015-09-18       Impact factor: 3.603

7.  Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hongmei Zhang; Yan Li; Marianna de Carvalho-Barbosa; Annemieke Kavelaars; Cobi J Heijnen; Phillip J Albrecht; Patrick M Dougherty
Journal:  J Pain       Date:  2016-03-12       Impact factor: 5.820

8.  Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Authors:  Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland
Journal:  J Pain       Date:  2015-07-22       Impact factor: 5.820

9.  Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.

Authors:  Xin Shelley Wang; Qiuling Shi; Patrick M Dougherty; Cathy Eng; Tito R Mendoza; Loretta A Williams; David R Fogelman; Charles S Cleeland
Journal:  Oncology       Date:  2016-02-17       Impact factor: 2.935

10.  Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.

Authors:  Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.